CNMD Stock Analysis: Buy, Sell, or Hold?
CNMD - CONMED Corporation
$34.79
-0.74 (-2.08%)
▼
5d:
-5.05%
30d:
-19.07%
90d:
-14.31%
HOLD
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: Apr 29, 2026
26d
Get Alerted When CNMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CNMD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CNMD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$64.45
Based on 8.6% avg growth
INTRINSIC VALUE TODAY
$40.02
13.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CNMD is currently trading at $34.79, which is considered oversold relative to its 30-day fair value range of $35.22 to $43.26. From a valuation perspective, the stock is trading at a discount (Forward PE: 7.1) compared to its historical average (8.7). Remarkably, the market is currently pricing in an annual earnings decline of 6.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CNMD is in a downtrend. Immediate support is located at $33.21, while resistance sits at $37.49.
Market Sentiment: CNMD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $44.20 (+27.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CNMD is in a downtrend. Immediate support is located at $33.21, while resistance sits at $37.49.
Market Sentiment: CNMD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $44.20 (+27.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$35.22 -
$43.26
Company Quality Score
50/100
(HOLD)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
59.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 27.0% below Wall St target ($44.20)
- CAUTION: 5-day price weakness (-5.0%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$35.22 -
$43.26
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$2.29
(6.6%)
Support & Resistance Levels
Support Level
$33.21
Resistance Level
$37.49
Current Trend
Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.06
Wall Street Target
$44.20
(+27.0%)
Revenue Growth (YoY)
7.9%
Earnings Growth (YoY)
-50.0%
Profit Margin
3.4%
Valuation Discount vs History
-6.6% cheaper
PE vs Historical
7.1 vs 8.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.6%
(market-implied from PE analysis)
1-Year Target
$32.49
(-7%)
2-Year Target
$30.35
(-13%)
3-Year Target
$28.35
(-19%)
3-Yr Target (if PE normalizes)
(PE: 7→9)
$34.92
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.6, Growth: 13.1%)
$146.70
(+322%)
Base:
(SPY PE: 7.1, Growth: 13.1%)
$50.36
(+45%)
Bear:
(PE: 6.0, Growth: 13.1%)
$42.81
(+23%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Trailing PE: 23.80 | Current EPS (TTM): $1.51
Bull Case
$79.07
(+116%)
Analyst growth 100.0%, PE expands to 26.2
Base Case
$71.88
(+96%)
Market implied 100.0%, PE stable at 23.8
Bear Case
$24.44
(-33%)
Severe decline -20.0%, PE contracts to 20.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.1 to 8.7
Stabilization Target:
$42.86
(+23.2%)
PE Expansion Potential:
+23.2%
Share & Embed Analysis
Last updated: April 02, 2026 5:41 PM ET
Data refreshes hourly during market hours. Next update: 6:41 PM
Data refreshes hourly during market hours. Next update: 6:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CNMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Richard Glaze
SELL
257 shares
2025-11-21
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 61 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 59 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 47 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 62 BUY |
